EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma

Nadia Ninosu, Susanne Melchers, Max Kappenstein, Nina Booken iD, Inga Hansen, Maël Blanchard iD, Emmanuella Guenova, Chalid Assaf iD, Sergij Goerdt, Jan P Nicolay

Cancers · 27.12.2023 · 16 (1) · 141

DOI: 10.3390/cancers16010141 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 27.12.2023. Verfasst von Nadia Ninosu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Primary cutaneous T-cell lymphomas (CTCLs) are rare lymphoproliferative malignancies characterized by significant morbidity and mortality in advanced disease stages. As curative approaches apart from allogeneic stem cell transplantation are lacking, establishing new treatment options, especially combination therapies, is crucial.

Methods

This retrospective study included 11 patients with SS or MF receiving therapy with mogamulizumab in combination with ECP from four European expert centers. The response rates in the skin and blood as well as treatment use and adverse events (AE) were described.

Results

8/11 patients (73%) showed an overall response (OR) in the skin. The mean mSWAT decreased from 98.2 ± 40.8 to 34.6 ± 23.8. The overall response rate (ORR) in the blood was 64% with two complete responses. During combination therapy, the mean number of Sézary cells decreased from 3365.3 × 106/L before treatment to 1268.6 × 106/L. The mean minimum known period without progress was 7.2 months in the skin and 7.6 months in the blood. The most common AEs were mogamulizumab-associated rash (MAR) (45.5%), anemia (27.3%), lymphocytopenia (27.8%), and infusion related reaction (16.7%). No AE led to treatment discontinuation.

Conclusions

Our study presents the combination of mogamulizumab and ECP as an effective therapy in the blood and skin in CTCL with good tolerability, similar to mogamulizumab monotherapy.

Schlagwörter

Stichwörter der Autor:innen

CTCLSézary syndromeextracorporeal photopheresismogamulizumabmycosis fungoides

Autor:innen und Institutionen

  • Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
  • Skin Cancer Unit, German Cancer Research Center, 69120 Heidelberg, Germany.
  • Section of Clinical and Experimental Dermatology, Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
  • Department of Hematology and Oncology, University Hospital of Schleswig-Holstein, Campus Lübeck, 23538 Lübeck, Germany.
  • Department of Dermatology and Venereology, University Skin Cancer Center Hamburg, University Medical Center Hamburg-Eppendorf, 20251 Hamburg, Germany.
  • Department of Dermatology, Lausanne University Hospital (CHUV) and Faculty of Biology and Medicine, University of Lausanne, 1007 Lausanne, Switzerland.

ORCID-Profile: Nina Booken, Maël Blanchard, Chalid Assaf

Zitieren

APA

Ninosu, N., Melchers, S., Kappenstein, M., Booken, N., Hansen, I., Blanchard, M., Guenova, E., Assaf, C., Goerdt, S., & Nicolay, J. P. (2023). Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma. Cancers, 16(1), 141. https://doi.org/10.3390/cancers16010141

Vancouver

Ninosu N, Melchers S, Kappenstein M, Booken N, Hansen I, Blanchard M, et al. Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma. Cancers. 2023;16(1):141. doi:10.3390/cancers16010141

BibTeX
@article{Ninosu2023,
  author = {Ninosu, Nadia and Melchers, Susanne and Kappenstein, Max and Booken, Nina and Hansen, Inga and Blanchard, Maël and Guenova, Emmanuella and Assaf, Chalid and Goerdt, Sergij and Nicolay, Jan P},
  title = {Mogamulizumab Combined with Extracorporeal Photopheresis as a Novel Therapy in Erythrodermic Cutaneous T-cell Lymphoma},
  journal = {Cancers},
  year = {2023},
  volume = {16},
  number = {1},
  pages = {141},
  doi = {10.3390/cancers16010141}
}
Kostenlos starten →